AXONICS MODULATION TECHNOLOGIES, U.K. LIMITED

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +4.5%

  £3,001,225 → £3,137,079

• Cash

  +191.1%

  £1,142,046 → £3,325,033

  highest in 5 filed years

• Net assets

  -39.3%

  -£49,642,552 → -£69,173,607

  lowest in 5 filed years

• Employees

  +25%

  4 → 5

• Operating profit

  -150.1%

  £4,111,561 → -£2,059,119

• Profit before tax

  -229.4%

  -£5,929,739 → -£19,533,164

• Wages

  -28.6%

  £603,623 → £430,818

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

MHA Audit Services LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the foregoing, these financial statements have been prepared on a going concern basis. The ultimate parent company has issued a letter of support for a period of at least 12 months from the date of the approval of the financial statements.”

Group structure

1. AXONICS MODULATION TECHNOLOGIES, U.K. LIMITED · parent
   1. Axonics Women's Health Limited 100% · United Kingdom · Intellectual Property Rights ('IPR') holder and distributor of pharmaceutical & medical devices.
   2. Axonics GmbH 100% · Germany · Distributor of pharmaceutical & medical devices.
   3. Bulkamid SARL 100% · France · Non-trading

Significant events

• “On 15 November 2024, Boston Scientific Corporation ('BSC')... acquired 100% of the issued shares capital of Axonics, Inc., the immediate parent company of the Company.”
• “On 1 May 2025, the Company entered into agreements with BSC Group companies to sell its commercial business, contracts with third-party distributors and distribution rights.”
• “On 20 March 2025, Axonics GmbH... was sold by the Company's subsidiary undertaking, Axonics Women's Health Limited to a fellow subsidiary undertaking in the BSC Group.”
• “Bulkamid SARL, an indirect subsidiary undertaking of the Company, was dissolved on 24 November 2025 and deregistered on 31 December 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

9

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.